A Study Of LY4584180 In Adult Participants With Previously Treated Blood Cancers

Overview

About this study

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:

* Diffuse large B-cell lymphoma - not otherwise specified
* High-grade B-cell lymphoma
* Diffuse large B-cell lymphoma - transformed from indolent lymphomas
* Follicular large B-cell lymphoma
* Follicular lymphoma
* Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

Exclusion Criteria:

* Has an active second cancer
* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or uncontrolled HIV
* Has known significant heart disease

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/26/2026. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mazie Tsang, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Jithma Abeykoon, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions